The global demand for Implantable Cardioverter Defibrillator (ICD) Market is presumed to reach the market size of nearly USD 15.37 BN by 2030 from USD 10.44 BN in 2022 with a CAGR of 4.95% under the study period 2023 - 2030.
An Implantable Cardioverter Defibrillator (ICD) is a medical device that is surgically implanted in a person's chest to monitor and treat irregular heartbeats, also known as arrhythmias. It is commonly used for patients who are at risk of sudden cardiac arrest (SCA) due to conditions such as ventricular tachycardia (VT) or ventricular fibrillation (VF), which are life-threatening arrhythmias that can lead to sudden cardiac death. ICDs are similar in appearance and function to pacemakers, but they are designed to provide both pacing and defibrillation capabilities.
Cardiovascular diseases, including conditions such as ventricular tachycardia (VT) and ventricular fibrillation (VF), which are indications for ICD implantation, are a leading cause of morbidity and mortality worldwide. As the global burden of cardiovascular diseases continues to scale up, there is an increasing demand for effective treatment options such as ICDs to manage and prevent life-threatening arrhythmias. Continuous advancements in ICD technology have improved the safety, efficacy, and functionality of these devices. For example, newer ICD models offer longer battery life, smaller device size, improved lead designs, remote monitoring capabilities, and advanced algorithms for arrhythmia detection and discrimination, among other features. These technological advancements have led to increased patient acceptance, improved outcomes, and expanded indications for ICD implantation, thereby driving market growth. There is a growing awareness among patients, healthcare providers, and caregivers about the benefits of ICDs in preventing sudden cardiac death.
ICDs are proven to be highly effective in terminating life-threatening arrhythmias and improving survival rates in patients at risk of sudden cardiac arrest. As awareness about the life-saving potential of ICDs increases, there is a greater demand for these devices, particularly among high-risk patient populations. The global population is ageing, and advanced age poses a significant risk for cardiovascular diseases and arrhythmias. Older adults are more prone to develop arrhythmias such as atrial fibrillation and heart failure, which may cause sudden cardiac death. Thus, there is a higher demand for ICDs to manage arrhythmias and prevent sudden cardiac arrest, thereby driving market growth. ICDs have become a standard of care for certain patient populations, such as those with prior episodes of sustained ventricular tachycardia or ventricular fibrillation, heart failure with reduced ejection fraction, and certain genetic conditions that increase the risk of sudden cardiac arrest. Clinical guidelines and recommendations from professional societies worldwide support the use of ICDs in these patients, leading to increased adoption and market growth.
Reimbursement policies and coverage for ICD implantation have a significant impact on market growth. In countries including the United States, Europe, and other developed regions, ICD implantation is reimbursed by public and private health insurance programs for eligible patients, which encourages the adoption of ICDs as a treatment option. Favourable reimbursement policies provide financial support to patients and healthcare providers, leading to increased uptake of ICDs and driving market growth. There is ongoing research and development in the field of ICDs, aimed at improving safety, efficacy, and patient outcomes. Manufacturers are investing in research to develop innovative ICD technologies, including new algorithms for arrhythmia detection, leadless ICDs, and wearable or external ICDs, among others. These ongoing efforts to advance ICD technology are expected to drive market growth by providing newer and more effective treatment options for patients at risk of life-threatening arrhythmias.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of implantable cardioverter defibrillator (icd). The growth and trends of implantable cardioverter defibrillator (icd) industry provide a holistic approach to this study.
This section of the implantable cardioverter defibrillator (icd) market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Product
By End User
This section covers the regional outlook, which accentuates current and future demand for the Implantable Cardioverter Defibrillator (ICD) market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the implantable cardioverter defibrillator (icd) market include Philips Healthcare, Defibtech, LLC., Asahi Kasei Corporation, Biotronik, LivaNova Plc, Abbott, Microport, Cardiac Science, Stryker, and CU Medical System Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Product
3.7.2 Market Attractiveness Analysis By End User
3.7.3 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) MARKET ANALYSIS BY PRODUCT
5.1 Overview by Product
5.2 Historical and Forecast Data
5.3 Analysis by Product
5.4 Transvenous Implantable Cardioverter Defibrillator (T-ICDs) Historic and Forecast Sales by Regions
5.5 Subcutaneous Implantable Cardioverter Defibrillator (S-ICDs) Historic and Forecast Sales by Regions
5.6 Cardiac Resynchronization Therapy Defibrillator (CRT-D) Historic and Forecast Sales by Regions
6 . GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) MARKET ANALYSIS BY END USER
6.1 Overview by End User
6.2 Historical and Forecast Data
6.3 Analysis by End User
6.4 Hospitals Historic and Forecast Sales by Regions
6.5 Ambulatory Surgical Centers Historic and Forecast Sales by Regions
7 . GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) MARKET ANALYSIS BY GEOGRAPHY
7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
7.3.1. Overview, Historic and Forecast Data Sales Analysis
7.3.2. North America By Segment Sales Analysis
7.3.3. North America By Country Sales Analysis
7.3.4. United State Sales Analysis
7.3.5. Canada Sales Analysis
7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
7.4.1. Overview, Historic and Forecast Data Sales Analysis
7.4.2. Europe by Segment Sales Analysis
7.4.3. Europe by Country Sales Analysis
7.4.4. United Kingdom Sales Analysis
7.4.5. France Sales Analysis
7.4.6. Germany Sales Analysis
7.4.7. Italy Sales Analysis
7.4.8. Russia Sales Analysis
7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
7.5.1. Overview, Historic and Forecast Data Sales Analysis
7.5.2. Asia Pacific by Segment Sales Analysis
7.5.3. Asia Pacific by Country Sales Analysis
7.5.4. China Sales Analysis
7.5.5. India Sales Analysis
7.5.6. Japan Sales Analysis
7.5.7. South Korea Sales Analysis
7.5.8. Australia Sales Analysis
7.5.9. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
7.6.1. Overview, Historic and Forecast Data Sales Analysis
7.6.2. Latin America by Segment Sales Analysis
7.6.3. Latin America by Country Sales Analysis
7.6.4. Brazil Sales Analysis
7.6.5. Argentina Sales Analysis
7.6.6. Peru Sales Analysis
7.6.7. Chile Sales Analysis
7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
7.7.1. Overview, Historic and Forecast Data Sales Analysis
7.7.2. Middle East & Africa by Segment Sales Analysis
7.7.3. Middle East & Africa by Country Sales Analysis
7.7.4. Saudi Arabia Sales Analysis
7.7.5. UAE Sales Analysis
7.7.6. Israel Sales Analysis
7.7.7. South Africa Sales Analysis
7.7.8. Rest Of Middle East And Africa Sales Analysis
8 . COMPETITIVE LANDSCAPE OF THE IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) COMPANIES
8.1. Implantable Cardioverter Defibrillator (Icd) Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments
9 . COMPANY PROFILES OF IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) INDUSTRY
9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Philips Healthcare
9.3.1. Company Overview
9.3.2. Company Revenue
9.3.3. Products
9.3.4. Recent Developments
9.4. Defibtech LLC.
9.4.1. Company Overview
9.4.2. Company Revenue
9.4.3. Products
9.4.4. Recent Developments
9.5. Asahi Kasei Corporation
9.5.1. Company Overview
9.5.2. Company Revenue
9.5.3. Products
9.5.4. Recent Developments
9.6. Biotronik
9.6.1. Company Overview
9.6.2. Company Revenue
9.6.3. Products
9.6.4. Recent Developments
9.7. LivaNova Plc
9.7.1. Company Overview
9.7.2. Company Revenue
9.7.3. Products
9.7.4. Recent Developments
9.8. Abbott
9.8.1. Company Overview
9.8.2. Company Revenue
9.8.3. Products
9.8.4. Recent Developments
9.9. Microport
9.9.1. Company Overview
9.9.2. Company Revenue
9.9.3. Products
9.9.4. Recent Developments
9.10. Cardiac Science
9.10.1. Company Overview
9.10.2. Company Revenue
9.10.3. Products
9.10.4. Recent Developments
9.11. Stryker
9.11.1. Company Overview
9.11.2. Company Revenue
9.11.3. Products
9.11.4. Recent Developments
9.12. CU Medical System Inc.
9.12.1. Company Overview
9.12.2. Company Revenue
9.12.3. Products
9.12.4. Recent Developments
*Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
LIST OF TABLES
LIST OF FIGURES
* Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
Avail customized purchase options to meet your exact research needs: